MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE

The invention discloses compounds of Formula (I):wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis and pharmaceutical compositions comprising the same. Also disclosed are methods for their production...

Full description

Saved in:
Bibliographic Details
Main Authors PICOLET, OLIVIER LAURENT, KYM, PHILIP R, MERAYO MERAYO, NURIA, MALAGU, KARINE FABIENNE, VAN DER PLAS, STEVEN EMIEL, PIZZONERO, MATHIEU RAFAËL, COUTY, SYLVAIN, YEUNG, MING C, DESROY, NICOLAS, MAI, THI THU TRANG, SEARLE, XENIA B, GFESSER, GREGORY A, HOUSSEMAN, CHRISTOPHER GAËTAN, WANG, XUEQING, ALTENBACH, ROBERT J, BOGDAN, ANDREW, LIU, BO
Format Patent
LanguageEnglish
Serbian
Published 31.08.2021
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention discloses compounds of Formula (I):wherein A1, R1, R2, R3, R4, and n are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis and pharmaceutical compositions comprising the same. Also disclosed are methods for their production and methods of treating cystic fibrosis by administering the compounds.
Bibliography:Application Number: RS2021P000973